Survie du greffon < Survie sans rechute < Survie tissulaire

Facettes : Author.f AffPays.f AffRegion.f AffVille.f AffOrg.f Mesh.f MeshFr.f KwdFr.f

List of bibliographic references indexed by Survie sans rechute

Number of relevant bibliographic references: 14.

Ident.	Authors (with country if any)	Title
000484 (2019)	Anbok Lee [Corée du Sud] ; Sunmi Jo [Corée du Sud] ; Changhu Lee [Corée du Sud] ; Hyun-Hee Shin [Corée du Sud] ; Tae Hyun Kim [Corée du Sud] ; Ki Jung Ahn [Corée du Sud] ; Sung-Kwang Park [Corée du Sud] ; Heunglae Cho [Corée du Sud] ; Hye-Kyoung Yoon [Corée du Sud] ; Woo Gyeong Kim [Corée du Sud] ; Jiyoung Park [Corée du Sud] ; Yunseon Choi [Corée du Sud]	Diabetes as a prognostic factor in HER-2 positive breast cancer patients treated with targeted therapy.
000596 (2019)	Pablo E. Serrano [Canada] ; Diana N. Carter [Canada] ; Christine Li [Canada] ; Marlie Valencia [Canada] ; Leyo Ruo [Canada] ; Sameer Parpia [Canada] ; Marko Simunovic [Canada] ; Oren Levine [Canada]	Adjuvant Chemotherapy With or Without Biologics Including Antiangiogenics and Monoclonal Antibodies Targeting EGFR and EpCAM in Colorectal Cancer: A Systematic Review and Meta-analysis.
000978 (2018)	Aideen M. Campbell [Royaume-Uni] ; Melanie Morris [Royaume-Uni] ; Rebecca Gallagher [Royaume-Uni] ; Ruth Boyd [Royaume-Uni] ; Hazel Carson [Royaume-Uni] ; D Paul Harkin [Royaume-Uni] ; Ewa Wielogorska [Royaume-Uni] ; Christopher Elliott [Royaume-Uni] ; Kienan I. Savage [Royaume-Uni] ; Stuart A. Mcintosh [Royaume-Uni]	Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment.
001094 (2016)	George Papaxoinis [Royaume-Uni] ; Kostas Syrigos [Grèce] ; Muhammad Wasif Saif [États-Unis]	New concepts in the treatment strategy of neuroendocrine tumors: the role of biotherapy.
001A91 (2014)	Kanako Shinjo [Japon] ; Yoriko Yamashita ; Eiko Yamamoto ; Shinya Akatsuka ; Nozomi Uno ; Akihiro Kamiya ; Kaoru Niimi ; Yuka Sakaguchi ; Tetsuro Nagasaka ; Takashi Takahashi ; Kiyosumi Shibata ; Hiroaki Kajiyama ; Fumitaka Kikkawa ; Shinya Toyokuni	Expression of chromobox homolog 7 (CBX7) is associated with poor prognosis in ovarian clear cell adenocarcinoma via TRAIL-induced apoptotic pathway regulation.
001C33 (2014)	E E W. Cohen [États-Unis] ; M. Tortorici ; S. Kim ; A. Ingrosso ; Y K Pithavala ; P. Bycott	A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses.
002063 (2012)	L H Jensen [Danemark] ; J. Lindebjerg [Danemark] ; J. Ploen ; T F Hansen ; A. Jakobsen	Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer.
002079 (2012)	Mei Dong [États-Unis] ; Alexandria T. Phan ; James C. Yao	New strategies for advanced neuroendocrine tumors in the era of targeted therapy.
002148 (2012)	Pierre Saintigny [États-Unis] ; Shaohua Peng ; Li Zhang ; Banibrata Sen ; Ignacio I. Wistuba ; Scott M. Lippman ; Luc Girard ; John D. Minna ; John V. Heymach ; Faye M. Johnson	Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion.
002507 (2011)	Ronan J. Kelly [États-Unis] ; Arun Rajan ; Jeremy Force ; Ariel Lopez-Chavez ; Corrine Keen ; Liang Cao ; Yunkai Yu ; Peter Choyke ; Baris Turkbey ; Mark Raffeld ; Liqiang Xi ; Seth M. Steinberg ; John J. Wright ; Shivaani Kummar ; Martin Gutierrez ; Giuseppe Giaccone	Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.
003136 (2006)	C I Chen [Canada] ; S. Nanji ; A. Prabhu ; R. Beheshti ; Q-L Yi ; D. Sutton ; A K Stewart	Sequential, cycling maintenance therapy for post transplant multiple myeloma.
003652 (2004)	Fabrizio Romano [Italie] ; Giovanni Cesana ; Mattia Berselli ; Maria Gaia Piacentini ; Roberto Caprotti ; Giorgio Bovo ; Franco Uggeri	Biological, histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients.
003D56 (1998)	J. Rusthoven ; V. Bramwell ; B. Stephenson	Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
004039 (1996)	P. Tosi [Italie] ; G. Visani ; E. Ottaviani ; S. Manfroi ; S. Tura	Biological and clinical significance of in vitro prednisolone resistance in adult acute lymphoblastic leukaemia.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/BiopestPeptidV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/MeshFr.i -k "Survie sans rechute" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/MeshFr.i  \
                -Sk "Survie sans rechute" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    BiopestPeptidV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    MeshFr.i
   |clé=    Survie sans rechute
}}

---

This area was generated with Dilib version V0.6.38. Data generation: Thu Nov 19 19:22:35 2020. Site generation: Thu Nov 19 19:33:26 2020